Royalty Pharma Plc: 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K, dated May 10, 2022, reports on the impact of the announced acquisition of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") by Pfizer Inc. ("Pfizer"). Royalty Pharma Plc ("Royalty Pharma") holds significant royalty, equity, and preferred share interests in Biohaven. The filing details the financial implications of the "Pfizer Acquisition" on Royalty Pharma's portfolio, assuming a closing in the first quarter of 2023.
Key Financial Metrics and Investment Impact
Royalty Pharma has invested approximately $835 million across four transactions with Biohaven. The Pfizer Acquisition is expected to accelerate cash inflows from equity and preferred share holdings while leaving royalty streams intact.
| Investment Type | Total Outflows | Expected Inflows (Post-Acquisition) | Multiple | Timing |
|---|---|---|---|---|
| Initial Royalty Transaction | $100 million | Unchanged | NA | NA |
| Second Royalty Transaction | $250 million | Unchanged | NA | NA |
| Common Equity | $87 million | ~$260 million | 3.0x | Q1 2023 |
| Series A Preferred Shares | $125 million | ~$250 million | 2.0x | Q1 2023 |
| Series B Preferred Shares | $200 million | ~$355 million | 1.8x | Q1 2023 |
Aggregate Equity Impact: For $412 million invested in common and preferred equity, Royalty Pharma expects to receive approximately $865 million, representing a 2.1x multiple. Proceeds of approximately $645 million are expected in Q1 2023 ($165 million from common equity; $480 million from preferred stock redemption).
Non-GAAP Impact: The $480 million preferred stock redemption is expected to generate approximately $455 million in Adjusted Cash Receipts for 2023. Common equity proceeds will be recorded in investing activities and will not impact Adjusted Cash Receipts or Adjusted Cash Flow.
Material Changes and Outlook
Royalty Streams: The acquisition has no impact on existing royalty agreements for Nurtec ODT and zavegepant. Royalty Pharma retains tiered royalties (2.1% up to $1.5 billion sales; 1.5% thereafter) and incremental royalties. These are expected to generate payments through 2034-2036.
Milestone Payments: Royalty Pharma is entitled to success-based milestones on zavegepant totaling up to $475 million for FDA approval in migraine, payable over 40 quarters. The filing states these milestones are not expected to be prepaid.
Guidance: Management does not expect the transaction to impact 2022 guidance or non-GAAP financial metrics, assuming a Q1 2023 closing.
Risks and Contingencies
- Closing Conditions: The Pfizer Acquisition is subject to regulatory approvals, shareholder approval, and the completion of a New Biohaven spin-off.
- Timing Assumptions: Financial projections assume a closing in early 2023. Delays could alter the timing of cash inflows.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future cash flows and multiples that are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the closing date of the Pfizer-Biohaven transaction to confirm the Q1 2023 cash inflow timeline.
- Confirm the final redemption price and terms for Series A and Series B Preferred Shares upon closing.
- Monitor FDA approval status for zavegepant in migraine to trigger the $475 million milestone payments.
- Review subsequent filings for any changes to the non-controlling interest distribution percentages (currently 17.6% for certain royalties).
- Assess the impact of the $645 million expected proceeds on Royalty Pharma's liquidity and potential for new investments or debt repayment.